Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Liabilities (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Total Liabilities for 13 consecutive years, with $104.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 14.83% year-over-year to $104.1 million, compared with a TTM value of $104.1 million through Dec 2025, down 14.83%, and an annual FY2025 reading of $104.1 million, down 14.83% over the prior year.
  • Total Liabilities was $104.1 million for Q4 2025 at Agios Pharmaceuticals, up from $101.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $191.8 million in Q1 2021 and bottomed at $89.0 million in Q1 2025.
  • Average Total Liabilities over 5 years is $127.3 million, with a median of $124.2 million recorded in 2023.
  • The sharpest move saw Total Liabilities crashed 67.86% in 2021, then soared 37.13% in 2024.
  • Year by year, Total Liabilities stood at $145.8 million in 2021, then decreased by 5.39% to $137.9 million in 2022, then dropped by 8.56% to $126.1 million in 2023, then dropped by 3.06% to $122.2 million in 2024, then fell by 14.83% to $104.1 million in 2025.
  • Business Quant data shows Total Liabilities for AGIO at $104.1 million in Q4 2025, $101.4 million in Q3 2025, and $101.7 million in Q2 2025.